Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 19/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31138099 | 1.00 | LPAR1 (0.47) | LPAR1LPAR3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL30538303 | 0.89 | LPAR1 (0.51) | LPAR1LPAR3 | |
| SCHEMBL25341148 | 0.89 | LPAR1 (0.51) | LPAR1LPAR3 | |
| SCHEMBL25341143 | 0.89 | LPAR1 (0.51) | LPAR1LPAR3 | |
| SCHEMBL31138096 | 0.89 | LPAR1 (0.49) | LPAR1LPAR3 | |
| SCHEMBL25955475 | 0.89 | LPAR1 (0.49) | LPAR1LPAR3 | |
| SCHEMBL25339138 | 0.87 | LPAR1 (0.59) | LPAR1LPAR3HRH1 | |
| SCHEMBL25339140 | 0.87 | LPAR1 (0.59) | LPAR1LPAR3HRH1 | |
| SCHEMBL31138079 | 0.86 | LPAR1 (0.45) | LPAR1LPAR3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL25955351 | 0.86 | LPAR1 (0.45) | LPAR1LPAR3CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250093-A1 | AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250093-A1 | AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885LPAR3 3/4885CHRNB2 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.